“The first deliveries of the drug were received by clinics and authorized pharmaceutical organizations in Moscow, Leningrad, Novgorod, Kirov, Nizhny Novgorod regions, the Republic of Tatarstan and Yekaterinburg,” the press release said.
In June, it is planned to deliver 60 thousand Avifavira courses to Russian hospitals.
Moreover, if necessary, the volume of production can be increased to 2 million courses per year.
Earlier, the newspaper Izvestia wrote that by the middle of next week Avifavir is planned to be produced in the required volume to satisfy the received applications from 35 regions.
At the end of May, the Russian Ministry of Health approved the Avifavir drug against coronavirus.